alcaftadine

DRUG2 trials

Sponsors

Vistakon Pharmaceuticals, Starx Research Center, LLC

Conditions

Allergic ConjunctivitisRhinoconjunctivitis

Phase 3

Safety and Efficacy Study of a Eye Drop for Eye Allergy

CompletedNCT00889330

Vistakon PharmaceuticalsAllergic Conjunctivitis

Start: 2009-04-30Updated: 2015-03-06

Phase 4

Ocular Allergy Treatment Practical Impact Trial

Starx Research Center, LLCAllergic Conjunctivitis, Rhinoconjunctivitis

Start: 2013-04-30End: 2013-11-30Target: 50Updated: 2013-05-30

Related Papers

The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis.

2011-01-2117 citations